Currently, testing potential patients in trials involves a liver biopsy, a risky procedure with limited accuracy. Among the new diagnostic tests being developed are MRI scans that allow for a view of the entire liver and blood tests to measure liver scarring or function. Another test involves the use of exhaled breath to evaluate liver function.
Additionally, the high price of some liver disease treatment drugs, such as Gilead’s Sovaldi for hepatitis C, are also prompting the development of new and more accurate diagnostic tests for liver disease, according to the report.
More articles on GI/endoscopy:
AGA Center for GI Innovation: “Getting to Zero” meeting for duodenoscope infections
AGA Diversity Committee expands sessions for DDW 2015
Syracuse hospitals fight infection with human waste
